Development and validation of a population pharmacokinetic model to guide perioperative tacrolimus dosing after lung transplantation
Background: Tacrolimus therapy is standard of care for immunosuppression after lung transplantation. However, tacrolimus exposure variability during the early postoperative period may contribute to poor outcomes in this population. Few studies have examined tacrolimus pharmacokinetics (PK) during th...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-11-01
|
| Series: | JHLT Open |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2950133424000831 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850198773014200320 |
|---|---|
| author | Todd A. Miano, PharmD, PhD Athena F. Zuppa, MD, MSCE Rui Feng, PhD Stephen Griffiths, BS Laurel Kalman, BA Michelle Oyster, MS Edward Cantu, MD, MSCE Wei Yang, PhD Joshua M. Diamond, MD, MSCE Jason D. Christie, MD, MSCE Marc H. Scheetz, PharmD, MSC Michael G.S. Shashaty, MD, MSCE |
| author_facet | Todd A. Miano, PharmD, PhD Athena F. Zuppa, MD, MSCE Rui Feng, PhD Stephen Griffiths, BS Laurel Kalman, BA Michelle Oyster, MS Edward Cantu, MD, MSCE Wei Yang, PhD Joshua M. Diamond, MD, MSCE Jason D. Christie, MD, MSCE Marc H. Scheetz, PharmD, MSC Michael G.S. Shashaty, MD, MSCE |
| author_sort | Todd A. Miano, PharmD, PhD |
| collection | DOAJ |
| description | Background: Tacrolimus therapy is standard of care for immunosuppression after lung transplantation. However, tacrolimus exposure variability during the early postoperative period may contribute to poor outcomes in this population. Few studies have examined tacrolimus pharmacokinetics (PK) during this high-risk period. Methods: We conducted a retrospective pharmacokinetic study in lung transplant recipients at the University of Pennsylvania who were enrolled in the Lung Transplant Outcomes Group cohort. We used nonlinear mixed-effects regression to derive a population PK model in 270 patients and examined validity in a separate cohort of 114 patients. Covariates were examined with univariate analysis and a multivariable model was developed using forward and backward stepwise selection. The performance of the final model in the validation cohort was examined with calculation of prediction error (PE). Results: We developed a 1-compartment base model with a fixed rate absorption constant. Covariates improving model fit were postoperative day, hematocrit, transplant type, CYP3A5 genotype, weight, and exposure to cytochrome p450 enzyme (CYP) inhibitor drugs. The strongest predictor of tacrolimus clearance was postoperative day, with median predicted clearance increasing more than 3-fold over the 14-day study period. In the validation cohort, the final model showed a mean PE of 36.4% (95% confidence interval 30.8%-41.9%) and a median PE of 7.2% (interquartile range −29.3% to 70.53%). Conclusions: Tacrolimus clearance is highly dynamic during the early postlung transplant period. Population PK models that include lung-transplant–specific covariates may enable precision dosing algorithms that account for this highly dynamic clearance. Future multicenters studies including a broader set of covariates are warranted. |
| format | Article |
| id | doaj-art-d342a6ab97e04758aad16f96d6b2db4f |
| institution | OA Journals |
| issn | 2950-1334 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JHLT Open |
| spelling | doaj-art-d342a6ab97e04758aad16f96d6b2db4f2025-08-20T02:12:46ZengElsevierJHLT Open2950-13342024-11-01610013410.1016/j.jhlto.2024.100134Development and validation of a population pharmacokinetic model to guide perioperative tacrolimus dosing after lung transplantationTodd A. Miano, PharmD, PhD0Athena F. Zuppa, MD, MSCE1Rui Feng, PhD2Stephen Griffiths, BS3Laurel Kalman, BA4Michelle Oyster, MS5Edward Cantu, MD, MSCE6Wei Yang, PhD7Joshua M. Diamond, MD, MSCE8Jason D. Christie, MD, MSCE9Marc H. Scheetz, PharmD, MSC10Michael G.S. Shashaty, MD, MSCE11Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Center for Real-world Effectiveness and Safety of Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Corresponding author: Todd A. Miano, PharmD, PhD, University of Pennsylvania, 809 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104.Johnson & Johnson, Horsham, PennsylvaniaDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PennsylvaniaPulmonary, Allergy, and Critical Care Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PennsylvaniaPulmonary, Allergy, and Critical Care Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PennsylvaniaPulmonary, Allergy, and Critical Care Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PennsylvaniaDivision of Cardiovascular Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PennsylvaniaDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Center for Real-world Effectiveness and Safety of Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PennsylvaniaPulmonary, Allergy, and Critical Care Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PennsylvaniaDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Pulmonary, Allergy, and Critical Care Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PennsylvaniaDepartment of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, Downers Grove, Illinois; Pharmacometrics Center of Excellence, Midwestern University, Downers Grove, IllinoisDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Pulmonary, Allergy, and Critical Care Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PennsylvaniaBackground: Tacrolimus therapy is standard of care for immunosuppression after lung transplantation. However, tacrolimus exposure variability during the early postoperative period may contribute to poor outcomes in this population. Few studies have examined tacrolimus pharmacokinetics (PK) during this high-risk period. Methods: We conducted a retrospective pharmacokinetic study in lung transplant recipients at the University of Pennsylvania who were enrolled in the Lung Transplant Outcomes Group cohort. We used nonlinear mixed-effects regression to derive a population PK model in 270 patients and examined validity in a separate cohort of 114 patients. Covariates were examined with univariate analysis and a multivariable model was developed using forward and backward stepwise selection. The performance of the final model in the validation cohort was examined with calculation of prediction error (PE). Results: We developed a 1-compartment base model with a fixed rate absorption constant. Covariates improving model fit were postoperative day, hematocrit, transplant type, CYP3A5 genotype, weight, and exposure to cytochrome p450 enzyme (CYP) inhibitor drugs. The strongest predictor of tacrolimus clearance was postoperative day, with median predicted clearance increasing more than 3-fold over the 14-day study period. In the validation cohort, the final model showed a mean PE of 36.4% (95% confidence interval 30.8%-41.9%) and a median PE of 7.2% (interquartile range −29.3% to 70.53%). Conclusions: Tacrolimus clearance is highly dynamic during the early postlung transplant period. Population PK models that include lung-transplant–specific covariates may enable precision dosing algorithms that account for this highly dynamic clearance. Future multicenters studies including a broader set of covariates are warranted.http://www.sciencedirect.com/science/article/pii/S2950133424000831tacrolimuslung transplantationpharmacokineticsprecision dosingpharmacogeneticscritical illness |
| spellingShingle | Todd A. Miano, PharmD, PhD Athena F. Zuppa, MD, MSCE Rui Feng, PhD Stephen Griffiths, BS Laurel Kalman, BA Michelle Oyster, MS Edward Cantu, MD, MSCE Wei Yang, PhD Joshua M. Diamond, MD, MSCE Jason D. Christie, MD, MSCE Marc H. Scheetz, PharmD, MSC Michael G.S. Shashaty, MD, MSCE Development and validation of a population pharmacokinetic model to guide perioperative tacrolimus dosing after lung transplantation JHLT Open tacrolimus lung transplantation pharmacokinetics precision dosing pharmacogenetics critical illness |
| title | Development and validation of a population pharmacokinetic model to guide perioperative tacrolimus dosing after lung transplantation |
| title_full | Development and validation of a population pharmacokinetic model to guide perioperative tacrolimus dosing after lung transplantation |
| title_fullStr | Development and validation of a population pharmacokinetic model to guide perioperative tacrolimus dosing after lung transplantation |
| title_full_unstemmed | Development and validation of a population pharmacokinetic model to guide perioperative tacrolimus dosing after lung transplantation |
| title_short | Development and validation of a population pharmacokinetic model to guide perioperative tacrolimus dosing after lung transplantation |
| title_sort | development and validation of a population pharmacokinetic model to guide perioperative tacrolimus dosing after lung transplantation |
| topic | tacrolimus lung transplantation pharmacokinetics precision dosing pharmacogenetics critical illness |
| url | http://www.sciencedirect.com/science/article/pii/S2950133424000831 |
| work_keys_str_mv | AT toddamianopharmdphd developmentandvalidationofapopulationpharmacokineticmodeltoguideperioperativetacrolimusdosingafterlungtransplantation AT athenafzuppamdmsce developmentandvalidationofapopulationpharmacokineticmodeltoguideperioperativetacrolimusdosingafterlungtransplantation AT ruifengphd developmentandvalidationofapopulationpharmacokineticmodeltoguideperioperativetacrolimusdosingafterlungtransplantation AT stephengriffithsbs developmentandvalidationofapopulationpharmacokineticmodeltoguideperioperativetacrolimusdosingafterlungtransplantation AT laurelkalmanba developmentandvalidationofapopulationpharmacokineticmodeltoguideperioperativetacrolimusdosingafterlungtransplantation AT michelleoysterms developmentandvalidationofapopulationpharmacokineticmodeltoguideperioperativetacrolimusdosingafterlungtransplantation AT edwardcantumdmsce developmentandvalidationofapopulationpharmacokineticmodeltoguideperioperativetacrolimusdosingafterlungtransplantation AT weiyangphd developmentandvalidationofapopulationpharmacokineticmodeltoguideperioperativetacrolimusdosingafterlungtransplantation AT joshuamdiamondmdmsce developmentandvalidationofapopulationpharmacokineticmodeltoguideperioperativetacrolimusdosingafterlungtransplantation AT jasondchristiemdmsce developmentandvalidationofapopulationpharmacokineticmodeltoguideperioperativetacrolimusdosingafterlungtransplantation AT marchscheetzpharmdmsc developmentandvalidationofapopulationpharmacokineticmodeltoguideperioperativetacrolimusdosingafterlungtransplantation AT michaelgsshashatymdmsce developmentandvalidationofapopulationpharmacokineticmodeltoguideperioperativetacrolimusdosingafterlungtransplantation |